Orient EuroPharma Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 10, 2023
Share
Orient EuroPharma Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was TWD 1,132.9 million compared to TWD 1,202.5 million a year ago. Net loss was TWD 189.03 million compared to TWD 97.25 million a year ago. Basic loss per share from continuing operations was TWD 2.18 compared to TWD 1.12 a year ago. Diluted loss per share from continuing operations was TWD 2.18 compared to TWD 1.12 a year ago.
For the six months, sales was TWD 2,283.73 million compared to TWD 2,346.01 million a year ago. Net loss was TWD 161.23 million compared to TWD 73.72 million a year ago. Basic loss per share from continuing operations was TWD 1.86 compared to TWD 0.85 a year ago. Diluted loss per share from continuing operations was TWD 1.86 compared to TWD 0.85 a year ago.
Orient Europharma Co., Ltd. is principally engaged in the manufacture and distribution of nutritious healthcare products and medical cosmetic products, as well as western drugs. The Company operates nutritious healthcare products and medical cosmetic products segment, providing infant milk powders, nutritious products and functional healthcare products, as well as dermatological preparations, medical hair care series, organic skin care series and medical make-up products, among others; western drugs segment, providing products for cardiovascular diseases, cancer, blood diseases, diabetes, central nervous system diseases and asthma, among others.